Holen Sie sich die Stockscreener-App
155.10
2.43%
3.68
Handel nachbörslich:
155.10
Schlusskurs vom Vortag:
$151.42
Offen:
$150.23
24-Stunden-Volumen:
426.26K
Relative Volume:
0.65
Marktkapitalisierung:
$10.04B
Einnahmen:
$74.06M
Nettoeinkommen (Verlust:
$-114.71M
KGV:
-85.98
EPS:
-1.8039
Netto-Cashflow:
$-117.90M
1W Leistung:
+6.33%
1M Leistung:
+18.15%
6M Leistung:
+90.33%
1J Leistung:
+182.05%
1-Tages-Spanne:
$149.17
$155.53
1-Wochen-Bereich:
$147.33
$155.53
52-Wochen-Spanne:
$54.18
$155.53
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Firmenname
Protagonist Therapeutics Inc
Sektor
Branche
Telefon
(510) 474-0170
Adresse
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
155.10 | 9.84B | 74.06M | -114.71M | -117.90M | -1.8039 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-12 | Eingeleitet | Leerink Partners | Outperform |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-12-06 | Eingeleitet | Goldman | Neutral |
| 2024-11-05 | Eingeleitet | Wedbush | Outperform |
| 2024-09-24 | Eingeleitet | TD Cowen | Buy |
| 2024-09-09 | Eingeleitet | Truist | Buy |
| 2023-10-30 | Eingeleitet | CapitalOne | Overweight |
| 2023-05-25 | Fortgesetzt | Jefferies | Buy |
| 2022-08-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-02-11 | Eingeleitet | BTIG Research | Buy |
| 2021-10-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-11 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-05-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-05-24 | Eingeleitet | Northland Capital | Outperform |
| 2021-01-06 | Eingeleitet | JP Morgan | Overweight |
| 2020-12-16 | Eingeleitet | Piper Sandler | Overweight |
| 2020-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-15 | Eingeleitet | Jefferies | Buy |
| 2020-05-18 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-05-09 | Hochstufung | Stifel | Hold → Buy |
| 2018-12-06 | Eingeleitet | Nomura | Buy |
| 2018-01-29 | Eingeleitet | Stifel | Buy |
| 2017-07-21 | Eingeleitet | BTIG Research | Buy |
Alle ansehen
Protagonist Therapeutics Inc Aktie (PTGX) Neueste Nachrichten
Johnson & Johnson Invests $300.22 Billion in Protagonist Therapeutics, Inc. $PTGX - marketbeat.com
Protagonist Therapeutics (NASDAQ:PTGX) Screens as an Affordable Growth Opportunity - ChartMill
Protagonist Therapeutics stock hits all-time high at 155.01 USD By Investing.com - Investing.com Nigeria
Protagonist Therapeutics stock hits all-time high at 155.01 USD - Investing.com
Farallon group (PTGX) discloses 6.43M-share, warrant‑backed stake in Protagonist - Stock Titan
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Recommendation of "Moderate Buy" by Brokerages - marketbeat.com
Protagonist Therapeutics, Inc. (PTGX) Stock Forecasts - Yahoo Finance
Protagonist Therapeutics CEO Dinesh Patel sells $14.9m in stock - Investing.com
Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $5,085,176.28 in Stock - marketbeat.com
Protagonist Therapeutics (NASDAQ:PTGX) CEO Dinesh Ph Patel Sells 65,761 Shares - marketbeat.com
Protagonist Therapeutics (PTGX) CEO sells 100,000 shares after option exercise - Stock Titan
(PTGX) Risk Channels and Responsive Allocation - Stock Traders Daily
Protagonist Therapeutics: 'Strong Buy' ICOTYDE FDA Approval And PN-881 Advancement (PTGX) - Seeking Alpha
Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 1-Year HighHere's Why - marketbeat.com
Protagonist Therapeutics CEO Dinesh Patel sells $14.9m in stock By Investing.com - Investing.com South Africa
Silence Therapeutics' Divesiran Data Support Best-in-Class Potential, Morgan Stanley Says - Yahoo Finance
PTGX (PTGX) insider files to sell 225,000 shares under Rule 144 - Stock Titan
PTGX Maintained by Truist Securities -- Price Target Raised to $170 - GuruFocus
PTGX Looks 105.7% Overvalued on GF Value™ - GuruFocus
PTGX Maintained by Wedbush -- Price Target Raised to $173 - GuruFocus
Protagonist upgraded at Goldman Sachs on potential of autoimmune asset - Seeking Alpha
Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Announces Target Price $170 - moomoo.com
PROTAGONIST THERAPEUTICS, INC. : WEDBUSH RAISES TARGET PRICE TO $173 FROM $118 - Bitget
Wedbush Adjusts PT on Protagonist Therapeutics to $173 From $118, Keeps Outperform Rating - moomoo.com
PTGX Upgraded by Goldman Sachs -- Price Target Raised to $186 - GuruFocus
Truist Adjusts Price Target on Protagonist Therapeutics to $170 From $145, Maintains Buy Rating - marketscreener.com
Goldman Sachs upgrades Protagonist Therapeutics stock rating on drug potential - Investing.com Australia
HC Wainwright Has Negative Forecast for PTGX FY2026 Earnings - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Rating Lowered to Buy at Wall Street Zen - marketbeat.com
Protagonist Therapeutics, Inc. Just Recorded A 21% EPS Beat: Here's What Analysts Are Forecasting Next - 富途牛牛
Surging Earnings Estimates Signal Upside for Protagonist Therapeutics (PTGX) Stock - Yahoo Finance
Protagonist Therapeutics (PTGX): State Street discloses 5.2% beneficial ownership stake - Stock Titan
A Quick Look at Today's Ratings for Protagonist Therapeutics(PTGX.US), With a Forecast Between $153 to $175 - moomoo.com
HC Wainwright Has Negative Forecast for PTGX Q3 Earnings - MarketBeat
PTGX Maintained by Citigroup -- Price Target Raised to $175 - GuruFocus
Bank of America Corp DE Has $136.54 Million Stock Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics stock hits all-time high at 143.43 USD By Investing.com - Investing.com UK
Protagonist Therapeutics, Inc. Stock 12‑Month Price Target Raised to $152.14, Implies 11% Upside - TradingView
Citigroup Forecasts Strong Price Appreciation for Protagonist Therapeutics (NASDAQ:PTGX) Stock - marketbeat.com
Protagonist Therapeutics stock hits all-time high at 143.43 USD - Investing.com
Protagonist Therapeutics (NASDAQ:PTGX) Hits New 12-Month High Following Strong Earnings - marketbeat.com
Protagonist Therapeutics2026 Funding Rounds & List of Investors - Tracxn
PROTAGONIST THERAPEUTICS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $167 FROM $117 - Bitget
Protagonist Therapeutics, Inc. $PTGX Shares Acquired by California State Teachers Retirement System - MarketBeat
PTGX SWOT Analysis: Strong Pipeline and Strategic Collaborations Highlighted in 10-Q Filing - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
Protagonist Therapeutics (PTGX) Beats Q2 Earnings Estimates - Yahoo Finance
Protagonist Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Protagonist Therapeutics, Inc 2026: Revenue $213.48M, EPS $2.29— 10-Q Summary - TradingView
Protagonist Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Earnings Flash (PTGX) Protagonist Therapeutics, Inc. Reports Q2 Revenue $213.5M, Vs. FactSet Est of $199.8M - moomoo.com
Finanzdaten der Protagonist Therapeutics Inc-Aktie (PTGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):